Kabeer Aziz is Director & 10% Owner at AN2 Therapeutics, Inc. (ANTX). They have made 6 open-market trades across 1 company since 2022, most recently 2026-10-12.
CIK 0001914847
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $2.5M since 2022, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANTX | 61,571 | $208K |
Shares reported on the most recent Form 4, priced at the 2026-10-13 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANTX | SELL | 2024-01-16 | 2024-01-18 | $19.65 | $3.9M | -1.8% | -81.3% | -87.5% |
| ANTX | SELL · 10b5-1 | 2023-11-14 | 2023-11-16 | $16.15 | $29K | -3.1% | +22.1% | -77.1% |
| ANTX | SELL | 2023-09-29 | 2023-10-03 | $16.27 | $3.4M | -1.3% | +6.3% | +40.8% |
| ANTX | SELL | 2023-09-27 | 2023-09-29 | $16.11 | $266K | -7.5% | -8.8% | +30.0% |
| ANTX | SELL · 10b5-1 | 2023-09-13 | 2023-09-15 | $16.00 | $6K | +9.2% | +2.7% | +40.9% |
| ANTX | SELL | 2023-09-06 | 2023-09-08 | $16.03 | $165K | -16.3% | -6.9% | +19.4% |
| ANTX | SELL | 2023-08-23 | 2023-08-25 | $16.00 | $6K | +3.3% | -9.1% | +14.6% |
| ANTX | BUY | 2022-03-29 | 2022-03-31 | $15.00 | $2.5M | -9.0% | +8.9% | -48.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.